Front Oncol: Efficacy and safety of pyrrotinib VS T-DM1 in patients with metastatic HER-2 positive treated breast cancer: from the Bayeux Meta-analysis

Before the advent of anti-HER2 therapies, patients with HER2-positive breast cancer had a poor prognosis
.

The clinical application of the first anti-HER2 drug trastuzumab has significantly improved the prognosis of patients with HER2-positive breast cancer

Before the advent of anti-HER2 therapies, patients with HER2-positive breast cancer had a poor prognosis

Research and search the PubMed, EMBASE, and Web of Science databases until August 2020
.

Randomized clinical studies comparing the efficacy and safety of different anti-HER2 regimens in patients with metastatic HER2-positive (≤second-line treatment) prior trastuzumab (Tra) and taxane in the treatment of advanced breast cancer were included

Research and search the PubMed, EMBASE, and Web of Science databases until August 2020

The study finally included 12 studies with a total of 4353 patients

All 12 studies reported progression-free survival (PFS) results

PFS comparison of different schemes

PFS comparison of different schemes

All 10 studies reported overall survival (OS) results
.

For overall survival (OS), Pyr-Cap is better than Lap-Cap (HR=0.

All 10 studies reported overall survival (OS) results

Comparison of different schemes of OS

Comparison of different schemes of OS

All 10 studies reported ORR results
.

For ORR, Pyr-Cap is better than Cap (ORR=7.

All 10 studies reported ORR results

There was no statistically significant difference between treatment strategies for ≥ grade 3 adverse events

In summary , studies suggest that pyrrotinib is more effective than T-DM1 in the treatment of patients with metastatic HER-2 positive breast cancer, but the occurrence of ≥3 grade adverse events is also higher

Original source:

Liao H, Huang W, Liu Y, Pei W, Li H.
Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
Front Oncol.
2021 May 3;11:608781.
doi: 10.
3389/fonc.
2021.
608781.
PMID: 34012912; PMCID: PMC8127838.

Liao H, Huang W, Liu Y, Pei W, Li H.
Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
Front Oncol.
2021 May 3;11:608781.
doi: 10.
3389/fonc.
2021.
608781.
PMID: 34012912; PMCID: PMC8127838.
Leave a message here